Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Paradigm shows good Phase 2 results, Race Oncology jumps 8pc after third party report on Zantrene
Health & Biotech
WEED WEEK: Wellnex teams up with Chemist Warehouse for new cannabis products
News
Market Highlights: Last hike? Market hopeful the Fed will pause; and a crackdown on crypto influencers
Health & Biotech
ASX Health Stocks: Emyria partners with Pax Centre to provide psychedelics therapy for PTSD sufferers
Health & Biotech
As dementia takes toll on Aussies, here’s why Alterity and these ASX biotechs are in the box seat
Health & Biotech
ASX Health Stocks: Emyria surges another 10pc; cannabis play Vitura delivers record profit
Health & Biotech
Weed Week: Greens reckon legal cannabis could generate $28 billion over a decade
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Not even the promise of top-shelf psychedelics could lift the market’s mood
News
ASX Small Caps Lunch Wrap: Who’s riding high on some psychedelic news this morning?
Health & Biotech
Australia just became the first country to recognise psychedelics as medicine. These are the ASX stocks you need to know about
News
Top 10 at 10: Which ASX stock is getting high on MDMA hype?
Health & Biotech
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
Health & Biotech
Weed Week: Aussie companies jostle to become the world’s supplier of medicinal cannabis
Health & Biotech
ASX Health Stocks: FDA greenlights Anteris study, Respiri selected in Arkansas
Health & Biotech
Weed Week: Oregon pardons cannabis convictions and bulk people light up on Turkey Day
Health & Biotech
